Correction to: Menatetrenone facilitates hematopoietic cell generation in a manner that is dependent on human bone marro
- PDF / 932,769 Bytes
- 4 Pages / 595.276 x 790.866 pts Page_size
- 80 Downloads / 122 Views
CORRECTION
Correction to: Menatetrenone facilitates hematopoietic cell generation in a manner that is dependent on human bone marrow mesenchymal stromal/stem cells Aya Fujishiro1,2 · Masaki Iwasa1,2 · Sumie Fujii1,3 · Taira Maekawa1 · Akira Andoh2 · Kaoru Tohyama4 · Akifumi Takaori‑Kondo3 · Yasuo Miura1,3 Published online: 15 September 2020 © Japanese Society of Hematology 2020
Correction to: International Journal of Hematology (2020) 112:316–330 https://doi.org/10.1007/s12185-020-02916-8
In addition, Y.M.’s grant should be “18K08323/Grantsin-Aid from the Ministry of Education, Culture, Sports, Science, and Technology in Japan”.
In the original publication of the article, the figures 4 C, F and 5 B, C were published with unexpected appearance of dots. The corrected Figs. 4, 5 are given in this correction.
The original article can be found online at https://doi.org/10.1007/ s12185-020-02916-8. * Aya Fujishiro [email protected]‑med.ac.jp 1
Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo‑ku, Kyoto 606‑8507, Japan
2
Division of Gastroenterology and Hematology, Department of Medicine, Shiga University of Medical Science, Setatsukinowacho, Otsu, Shiga 520‑2192, Japan
3
Department of Hematology and Oncology, Kyoto University Graduate School for Medicine, 54 Kawaharacho, Shogoin, Sakyo‑ku, Kyoto 606‑8507, Japan
4
Department of Laboratory Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701‑0192, Japan
13
Vol.:(0123456789)
600 Fig. 4 Menatetrenone does not affect the differentiation or prolif- ▸ eration capabilities of BM-MSCs. a, b Osteogenic differentiation of BM-MSCs treated with or without menatetrenone, as assessed by Alizarin Red S staining (a). Red nodules indicate mineralization (b). Representative images are shown. c Expression levels of osteogenesis-associated genes in BM-MSCs treated with or without menatetrenone, as assessed by qRT-PCR. RUNX2 runt-related transcription factor 2, OSX osterix, COL collagen, ALP alkaline phosphatase, OPN osteopontin, OCN osteocalcin. d, e Adipogenic differentiation of BM-MSCs treated with or without menatetrenone, as assessed by Oil Red O staining (d). Red-staining indicates fat-laden cells (e). Representative images are shown. f The proliferation of BM-MSCs treated with or without menatetrenone. a, c, d, f Data are represented as the mean ± SD; n = 5 per group; n.s. not significant
A. Fujishiro et al.
A
B
C
D
F
13
E
Correction to: Menatetrenone facilitates hematopoietic cell generation in a manner that is… Fig. 5 Direct cell–cell interactions, but not soluble factors, mediate enhanced HPC expansion in co-cultures with menatetrenone-treated human BM-MSCs. a Cytokine arrays of supernatants from cultures of BM-MSCs treated with 0, 1, or 10 µM menatetrenone. CCL2 C–C motif chemokine ligand 2, CXCL12 C-X-C motif chemokine ligand 12, MIF macrophage migration inhibitory factor, SERPINE1 serpin family E member 1, IL-6 interleukin-6. b The mRNA expression level
Data Loading...
